No headlines found.
Inventiva to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
Globe Newswire (Wed, 4-Feb 4:00 PM ET)
Half-Year Review of Inventiva's Liquidity Contract with Kepler Cheuvreux
Globe Newswire (Mon, 26-Jan 4:00 PM ET)
Inventiva to Present at the 44th Annual J.P. Morgan Healthcare Conference
Globe Newswire (Wed, 17-Dec 4:00 PM ET)
Results of the Votes of the Combined Shareholders' General Meeting of November 27, 2025
Globe Newswire (Fri, 28-Nov 2:30 AM ET)
Inventiva reports 2025 Third Quarter Financial Information
Globe Newswire (Fri, 21-Nov 4:00 PM ET)
Globe Newswire (Mon, 17-Nov 2:30 AM ET)
Inventiva announces trading resumption of its ordinary shares on Euronext Paris
Globe Newswire (Thu, 13-Nov 10:24 AM ET)
Globe Newswire (Thu, 13-Nov 9:22 AM ET)
Inventiva announces temporary trading halt of its ordinary shares on Euronext Paris
Globe Newswire (Thu, 13-Nov 2:40 AM ET)
Inventiva announces launch of public offering
Globe Newswire (Wed, 12-Nov 4:25 PM ET)
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.
Inventiva S.A. - American Depository Shares trades on the NASDAQ stock market under the symbol IVA.
As of February 6, 2026, IVA stock price climbed to $5.88 with 291,611 million shares trading.
IVA has a beta of 0.09, meaning it tends to be less sensitive to market movements. IVA has a correlation of 0.00 to the broad based SPY ETF.
IVA has a market cap of $1.13 billion. This is considered a Small Cap stock.
Last quarter Inventiva S.A. - American Depository Shares reported $5 million in Revenue and -$1.84 earnings per share. This fell short of revenue expectation by $-260,000 and missed earnings estimates by -$1.43.
In the last 3 years, IVA traded as high as $7.98 and as low as $1.53.
IVA has outperformed the market in the last year with a return of +132.5%, while the SPY ETF gained +15.1%. In the last 3 month period, IVA beat the market returning +40.7%, while SPY returned +3.3%. However, in the most recent 2 weeks IVA has underperformed the stock market by returning -17.8%, while SPY returned +0.2%.
IVA support price is $5.53 and resistance is $6.08 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IVA shares will trade within this expected range on the day.
